PaySign, Inc.

PaySign, Inc. (PAYS) Market Cap

PaySign, Inc. has a market capitalization of $358.7M.

Financials based on reported quarter end 2025-12-31

Price: $6.50

0.19 (3.00%)

Market Cap: 358.66M

NASDAQ · time unavailable

CEO: Mark R. Newcomer

Sector: Technology

Industry: Software - Infrastructure

IPO Date: 2007-10-10

Website: https://www.paysign.com

PaySign, Inc. (PAYS) - Company Information

Market Cap: 358.66M · Sector: Technology

PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. It offers various services, such as transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary card-processing platform. The company also develops prepaid card programs for corporate incentive and rewards, including consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, it offers and Per Diem/Corporate Expense Payments that allows businesses, and non–profits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, the company provides payment claims processing and other administrative services; pharmacy-based voucher and copay, and medical claims and debit-based affordability programs; PaySign Premier, a demand deposit account debit card; and payment solution for source plasma collection centers, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. was incorporated in 1995 and is based in Henderson, Nevada.

Analyst Sentiment

63%
Buy

Based on 8 ratings

Analyst 1Y Forecast: $7.67

Average target (based on 2 sources)

Consensus Price Target

Low

$9

Median

$9

High

$9

Average

$9

Potential Upside: 38.5%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PAYSIGN INC (PAYS) — Investment Overview

🧩 Business Model Overview

PAYS operates in the payments value chain as an enabler between merchants/end-users and financial rails. The business typically sits in the “collect–route–settle” layer: it helps businesses and institutions offer payment acceptance and payment-linked services, and it orchestrates the flow of funds and related data through partner banking/payment networks. Revenue is generated from processing and value-added services rather than from owning the underlying banking balance sheet.

Customer stickiness is driven by operational integration and relationship maturity. Once merchants, distributors, or institutional partners are onboarded, ongoing use depends on stable settlement performance, reconciliation accuracy, partner network uptime, and service-level responsiveness—creating a workflow dependency rather than a one-off transaction.

💰 Revenue Streams & Monetisation Model

Monetisation is primarily transactional (fees per processed transaction, service charges, and payment-linked charges), with a meaningful component of repeat usage that behaves “recurringly” because payment volumes tend to persist with business activity. Margin structure is shaped by:

  • Mix of fee types: higher-margin value-added services (risk/controls, reconciliation tooling, payout/collection add-ons) can offset lower-margin pure processing.
  • Processing scale: fixed operating costs (technology, compliance, operations) are spread over transaction volume, improving contribution margins as throughput rises.
  • Settlement economics: net economics depend on payment routing, partner pricing, and chargebacks/failures—areas where operational excellence can improve profitability.
  • Client retention: durable relationships can reduce customer acquisition costs per active client and support stable revenue.

Overall, the business model can exhibit operating leverage when growth comes from adding transaction throughput and service depth rather than from purely linear headcount growth.

🧠 Competitive Advantages & Market Positioning

The structural moat is primarily switching costs, reinforced by operational scale and, where applicable, workflow/network integration effects.

  • Switching costs (hard to replicate): integration into merchant/institution workflows (APIs, reconciliation, reporting, settlement processes, compliance controls) makes replacement costly in time and risk. Migration typically requires remapping payment flows, retraining teams, and validating settlement and dispute handling.
  • Compliance and risk operations: payments businesses must maintain robust fraud controls, KYC/AML adherence (directly or via partners), and audit-ready reporting. Process maturity becomes an execution advantage that competitors cannot quickly “buy” without a comparable operational history.
  • Partner ecosystem: a dense network of banking/payment partners and payout rails improves acceptance/coverage and can reduce failure rates. While not a “classic” network effect, it creates practical friction for challengers attempting to match routing quality.

A credible competitor can enter the market, but displacing incumbent volume at scale typically requires matching both product functionality and end-to-end operational performance—an evidence- and track-record-driven barrier.

🚀 Multi-Year Growth Drivers

The investment case over a 5–10 year horizon rests on secular expansion of electronic payments and digitization of merchant and institutional cash flows. Key growth drivers include:

  • Increase in addressable transaction volume: payments penetration and the shift from cash/inefficient settlement to faster digital rails expand the total processing opportunity.
  • Merchant digitization and payments acceptance depth: growing adoption among SMEs and expanding payment acceptance needs (multiple rails, settlement options, reconciliation tooling) increase “service attachment.”
  • Product expansion: layering value-added services (risk controls, reconciliation and reporting, payout/collection workflows, and compliance tooling) increases revenue per active client and improves overall margins.
  • Regional and segment-level penetration: durable onboarding pipelines across underserved segments can translate into compounding active client count and transaction frequency.
  • Operational leverage: scalable technology and process standardization can improve unit economics as transaction volumes rise without proportional increases in operating costs.

The core thesis is not merely growth in processing volume, but the ability to convert that volume into sustainable profitability through mix improvement and operational execution.

⚠ Risk Factors to Monitor

  • Regulatory and compliance risk: changes to payment regulations, KYC/AML requirements, dispute handling, settlement rules, or partner eligibility can compress economics or slow onboarding.
  • Competitive pressure and pricing: increased competition among payment processors can drive down take rates, particularly for commoditized transaction processing.
  • Fraud, chargebacks, and risk losses: deterioration in underwriting/routing quality can increase costs and create earnings volatility.
  • Technology and cybersecurity: payment platforms are high-value targets; outages, integration failures, or security incidents can impair trust and retention.
  • Partner concentration and dependency: reliance on banking/payment partners for routing, settlement, and coverage can expose the business to partner policy or pricing changes.
  • Working capital and operational settlement dynamics: depending on structure, settlement timing and funding mechanics can introduce cash flow stress during high-growth phases.

📊 Valuation & Market View

Markets typically value payments infrastructure businesses using a blend of revenue quality and operating leverage rather than only growth rate. Common frameworks include:

  • Price-to-sales (P/S): used when earnings visibility is still developing; higher-quality, recurring-like transaction revenue supports premium multiples.
  • EV/EBITDA (or EV/EBIT): increasingly relevant when operating discipline and cost leverage are evident.
  • Unit economics focus: investors pay attention to contribution margin trends, cost-to-serve, loss rates (fraud/chargebacks), and retention/active client growth.

Drivers that tend to move valuation include: improving fee mix toward higher-margin services, stable risk performance, evidence of scalable cost structure, and resilience in client retention and transaction depth.

🔍 Investment Takeaway

PAYS offers an attractive long-term profile for investors seeking exposure to the digitization of commerce through a payments enablement model. The central thesis is built on structural switching costs from operational integration, reinforced by compliance/risk operational maturity and partner ecosystem execution. Over time, the key question is whether the company can convert transaction growth into sustainable margin expansion via fee mix improvement, controlled risk outcomes, and scalable operations.


⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"PAYS reported revenue of $22.76M for the fiscal year ending December 31, 2025, with a net income of $1.36M and earnings per share (EPS) of $0.024. The company generated an operating cash flow of $6.75M and a free cash flow of $8.01M, showing strong retained cash generation despite no dividends being paid. Total assets stand at $276.25M against total liabilities of $227.76M, resulting in total equity of $48.49M; additionally, the company's net debt is negative at -$15.04M, indicating a cash-rich position. Over the past year, shares of PAYS have appreciated by 49.60%, reflecting strong market performance despite a recent pullback. The current market price is $3.77, with a price target consensus at $9, indicating significant potential upside. Overall, PAYS demonstrates solid revenue growth, healthy balance sheet management, and an attractive price point, positioning it well in the retail sector."

Revenue Growth

Positive

Strong revenue growth observed; up from previous periods.

Profitability

Neutral

Positive net income, but margin levels could improve.

Cash Flow Quality

Good

Robust cash flow generation from operating activities.

Leverage & Balance Sheet

Strong

Strong balance sheet with negative net debt indicating cash reserves.

Shareholder Returns

Good

Significant price appreciation over the last year with no dividends.

Analyst Sentiment & Valuation

Good

Price target indicates upside potential, aligning with market sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management highlighted a clear inflection in profitability: full-year operating margin expanded 723 bps to 9% and adjusted EBITDA grew 107% to $19.9M, backed by +40.5% revenue growth to $82M. The core engine is patient affordability—55 net new programs in 2025 to 131 total, ~79% claims processing growth, and client savings of >$325M (nearly $150M already in 2026). Plasma is framed as a cash-cow with growth increasingly driven by ~10% capacity gains from hardware upgrades rather than new center openings. In the Q&A, analyst pressure centered on (1) whether pharma customers are slowing initiatives and (2) how GLP-1 fits the co-pay model. Management pushed back strongly on slowdown risk, and argued weight-loss GLP-1 upside is limited due to DTC dynamics, while they see a potential path on the diabetes side. The main operational hurdle remains FDA 510(k) timing for BECS (expected within 60 days), but otherwise answers were confident and growth-oriented.

AI IconGrowth Catalysts

  • Patient affordability platform: added 55 net programs in 2025; total active programs reached 131
  • Dynamic business rules ROI: saved clients >$325M in 2025; already saved almost $150M so far in 2026
  • Patient affordability scale: claims processed increased ~79% in 2025
  • Plasma donor compensation growth from center capacity utilization (hardware upgrades increasing per-center capacity)

Business Development

  • 6 of the top 10 U.S. pharmaceutical manufacturers now have active patient affordability programs with Paysign
  • One large pharmaceutical manufacturer onboarded in 2024 scaled through 2025; Paysign added 4 additional programs from the same manufacturer during 2025
  • GLP-1: company has 1 client with a GLP-1 product (diabetes side) expected to come to market; they do not have the 2 larger weight-loss GLP-1s or diabetes products (as stated)
  • Conference/pipeline: attending Asembia Specialty Pharmacy Summit next month (Las Vegas) with a “robust pipeline”

AI IconFinancial Highlights

  • Full year revenue: +40.5% to $82.0M (from context: 40.5% to $82M stated)
  • Full year net income: +98% to $7.6M
  • Full year adjusted EBITDA: +107% to $19.9M
  • Operating margin expansion: +723 bps (from ~1.7% to 9% stated) as operating leverage kicked in
  • Gross profit margin: 59.4% vs 55.1% prior year in 2025
  • Q4 earnings: earnings before taxes $2.5M vs $1.2M prior year quarter
  • Q4 tax rate: effective tax rate 45.4% reduced EPS by $0.02 (fully diluted) vs prior period
  • Q4 adjusted EBITDA: $5.4M or $0.09 per diluted share vs $2.9M or $0.05 prior year quarter
  • Plasma revenue: $45.6M (+4% vs $43.9M) driven by +115 net plasma centers, offset by reduced average donations/center due to elevated inventory in 2025
  • Other revenue: +$671k (+36.2%) driven by growth in cardholders in payroll/retail/corporate incentive programs

AI IconCapital Funding

  • Cash: exited 2025 with $21.1M cash (nearly double prior year); excludes pass-through receivables/payables in pharma program flows
  • Debt: zero bank debt
  • Funding: Gamma acquisition funded through operating cash flow

AI IconStrategy & Ops

  • Plasma: expects revenue growth driven primarily by center filling excess capacity rather than new center openings; said market share maintained at just under 50%
  • Plasma center count: exited 2025 with 595 centers (up 115 from 480 end of 2024)
  • FDA regulatory hurdle: awaiting FDA 510(k) review for donor management system (BECS); integration work underway and BECS integration included in latest FDA filing
  • Hardware/ops: plasma center capacity expected to rise ~10% from latest hardware upgrades; framing: 10 centers now equal ~11 centers worth of capacity, reducing demand for new openings
  • SG&A discipline: 2026 expects OpEx up ~20% but controlling controllable SG&A; SG&A growth targeted at 20%, with noted components like amortization and stock comp

AI IconMarket Outlook

  • 2026 revenue guidance: $106.5M to $110.5M (30% to 35% YoY growth); plasma and pharma contributing equally; other revenue $2.5M
  • 2026 gross margin guidance: 60% to 62% (driven by increased pharma patient affordability mix)
  • 2026 operating margin / profitability: net income expected to nearly double to $13M to $16M (=$0.21 to $0.26 per diluted share); adjusted EBITDA $30M to $33M (=$0.49 to $0.53 per diluted share)
  • 2026 tax rate: estimated 22.5% to 25%
  • Q1 2026 revenue guidance: $27.0M to $27.5M (45.2% to 47.8% YoY growth)
  • Q1 2026 program counts: 137 active patient affordability programs; 589 plasma centers exiting the quarter
  • Q1 2026 margin guidance: operating margin 20% to 22%; net margin 17% to 19%; adjusted EBITDA margin 34.5% to 36.5%
  • Q1 2026 EPS: $0.07 to $0.08; adjusted EBITDA per share $0.15 to $0.16
  • Plasma seasonality: plasma revenue lowest in Q1 due to tax refunds going out; ramp thereafter; pharma highest in Q1 and declines through the remainder of the year as patient affordability claims ramp down

AI IconRisks & Headwinds

  • Regulatory timing risk: FDA response for Nuvec donor management system (BECS) expected within next 60 days; timeline uncertainty could delay installations/transitions
  • Plasma revenue headwind already experienced in 2025: reduced average plasma donations per center due to elevated plasma inventory levels, lowering average monthly revenue per center despite more centers
  • GLP-1 product mismatch risk: company does not have the two larger weight-loss GLP-1s (or diabetes products); management expects limited co-pay program volume upside for weight-loss GLP-1s because they are more DTC than co-pay driven
  • Investor perception risk (from Q&A, incomplete): management referenced a ‘show-me’ stance and possible concerns around whether AI affects dynamic business rules/ability to benefit, but transcript cuts off before specific quantified impact or mitigation details

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the PAYS Q4 and Full Year 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (PAYS)

© 2026 Stock Market Info — PaySign, Inc. (PAYS) Financial Profile